Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement

Arthritis Res Ther. 2010;12(2):R37. doi: 10.1186/ar2946. Epub 2010 Mar 2.

Abstract

Introduction: Urokinase-type plasminogen activator (u-PA) has been implicated in fibrinolysis, cell migration, latent cytokine activation, cell activation, T-cell activation, and tissue remodeling, all of which are involved in the development of rheumatoid arthritis. Previously, u-PA has been reported to play a protective role in monoarticular arthritis models involving mBSA as the antigen, but a deleterious role in the systemic polyarticular collagen-induced arthritis (CIA) model. The aim of the current study is to determine how u-PA might be acting in systemic arthritis models.

Methods: The CIA model and bone marrow chimeras were used to determine the cellular source of u-PA required for the arthritis development. Gene expression of inflammatory and destructive mediators was measured in joint tissue by quantitiative PCR and protein levels by ELISA. The requirement for u-PA in the type II collagen mAb-induced arthritis (CAIA) and K/BxN serum transfer arthritis models was determined using u-PA(-/-) mice. Neutrophilia was induced in the peritoneal cavity using either ovalbumin/anti-ovalbumin or the complement component C5a.

Results: u-PA from a bone marrow-derived cell was required for the full development of CIA. The disease in u-PA(-/-) mice reconstituted with bone marrow from C57BL/6 mice was indistinguishable from that in C57BL/6 mice, in terms of clinical score, histologic features, and protein and gene expression of key mediators. u-PA(-/-) mice were resistant to both CAIA and K/BxN serum transfer arthritis development. u-PA(-/-) mice developed a reduced neutrophilia and chemokine production in the peritoneal cavity following ovalbumin/anti-ovalbumin injection; in contrast, the peritoneal neutrophilia in response to C5a was u-PA independent.

Conclusions: u-PA is required for the full development of systemic arthritis models involving immune complex formation and deposition. The cellular source of u-PA required for CIA is bone marrow derived and likely to be of myeloid origin. For immune complex-mediated peritonitis, and perhaps some other inflammatory responses, it is suggested that the u-PA involvement may be upstream of C5a signaling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arthritis, Experimental / genetics*
  • Arthritis, Experimental / metabolism
  • Arthritis, Experimental / pathology
  • Arthritis, Rheumatoid / genetics*
  • Arthritis, Rheumatoid / immunology
  • Arthritis, Rheumatoid / metabolism
  • Bone Marrow Cells / metabolism
  • Bone Marrow Cells / pathology
  • Collagen / immunology
  • Collagen / pharmacology
  • Cytokines / metabolism
  • Female
  • Gene Expression*
  • Hindlimb
  • Immune Complex Diseases / genetics*
  • Immune Complex Diseases / immunology
  • Immune Complex Diseases / metabolism
  • Immunohistochemistry
  • Joints / metabolism
  • Joints / pathology
  • Male
  • Matrix Metalloproteinase 9 / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Neutrophils / immunology
  • Ovalbumin / pharmacology
  • Peritonitis / genetics
  • Peritonitis / immunology
  • Peritonitis / metabolism
  • Urokinase-Type Plasminogen Activator / deficiency
  • Urokinase-Type Plasminogen Activator / genetics*

Substances

  • Cytokines
  • Ovalbumin
  • Collagen
  • Urokinase-Type Plasminogen Activator
  • Matrix Metalloproteinase 9